Return to homepagePandemic Pact

Development of pan-flaviviral protease inhibitors

  • Funded by National Health and Medical Research Council (NHMRC)
  • Total publications:0 publications

Grant number: GA521973

Grant search

Key facts

  • Disease

    Zika virus disease, Congenital infection caused by Zika virus…

  • Start & end year

    2026
    2028

  • Known Financial Commitments (USD)

    $739,632.31

  • Funder

    National Health and Medical Research Council (NHMRC)

  • Research Location

    Australia, Germany

  • Lead Research Institution

    Monash University

  • Research Priority Alignment

    N/A

  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Pre-clinical studies

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

This project aims to develop drug candidates against flavivirus infections. Flaviviruses are transmitted to humans by insect bites and can cause severe infectious diseases. Many arboviruses circulate in Australia with the potential of explosive future outbreaks. This project will target viral enzymes called proteases which are essential for viral replication. The project aims to develop different types of protease inhibitors that may be active against a whole range of flaviviruses.